

TECHNION – RUTH & BRUCE RAPPAPORT FACULTY OF MEDICINE

RESUME

1. PERSONAL DETAILS

Full Name: Rahamim (Rami) Ben-Yosef

Identify No: 05359322-4

Date and place of birth: October 29, 1955, Hadera, Israel

Marital status: Married + 4

Phone numbers: 972-50-2061633, 972-4-7771812, 972-2-5336207

E-mail: r_ben-yosef@rambam.health.gov.il; rami@benyosef.co.il

2. ACADEMIC DEGREES

MD, 1980, Hadassah-Hebrew University school of medicine

3. ACADEMIC APPOINTMENTS

2013-2016: Associate Professor, Technion school of medicine, Haifa, Israel

2007-2012: Associate Professor, School of Medicine, Tel Aviv University, Tel Aviv, Israel

2001-2007: Senior Lecturer, School of Medicine, Tel Aviv University, Tel Aviv, Israel

1986-1990: Instructor, Hebrew University School of Medicine, Jerusalem, Israel

4. PROFESSIONAL EXPERIENCE

1995-1999: Fellow, BMT Unit, Hadassah Medical Center, Jerusalem, Israel

1995: Fellow, Gray Laboratory cancer research, Mount Vernon Hospital, Norhtwood, UK

1990-1993: Fellow, Radiation Oncology, Stanford University, Palo Alto, USA

1984-1990: Resident, Department of Oncology, Hadassah Medical Center, Jerusalem, Israel

1980-1981: Internship, Rambam Health Care Center, Haifa, Israel.

5. RESEARCH INTERESTS

1. Implementation of hyperthermia, combined with radiation therapy and chemotherapy, in cancer patients. Currently running a international, multi-istitutional phase II study in heat sensitive liposomal Adriamycin with XRT and HT for breast cancer (committee member).

2. Development of new devices and new techniques in delivering radiation therapy for cancer patients as (a) implant of degradable balloon to decrease radiation dose to normal tissues (b) developing a contrast long acting solution for delineating tumor volume during radiation therapy period. (c) Development and utilization of brain and body stereotactic radiation techniques to primary tumors and to oligometastases.

6. TEACHING EXPERIENCE

1985-present: Principles and practice of radiation and clinical oncology to medical students in Technion, Tel Aviv and Hebrew universities during their clinical years.

2003-06: Radiation Oncology, MSc students, School of Medicine, Tel Aviv University

2003, 2005, 2010, 2011: Radiation Oncology, Continuous Education Program for MDs, School of Medicine, Tel Aviv University

7. TECHNION ACTIVITIES

2015-present: Judge in disciplinary tribunal

8. FACULTY ACTIVITIES

None

9. PUBLIC PROFESSIONAL ACTIVITIES

2016: Organizing committee of radiation oncology in national annual ISCORT meeting.

2015- present: MD member in regional labor court

2013- present: Critic Committee, Israeli Society for Clinical Oncology and Radiation Therapy

2008-present: Member in editorial board The open postate cancer journal

2009-10 Member, Grant Committee, Tel Aviv University School of Medicine

2007-10 Member, Regulation Committee for Conducting Research in Animals, Sourasky Medical Center, Tel Aviv

2005-10 Member, Helsinki Committee, Sourasky Medical Center, Tel Aviv

2006-08 Member, Cancer Prevention Committee, Israel Cancer Association

2002-08 Member, Executive Committee, Israeli Uro-Oncology Group

2003-08 Head, Critic and Ethical Committee, Israeli Society for Clinical Oncology and Radiation Therapy

1998-present: MD consultant for national defense office and national insurance institute

10. MEMBERSHIP IN PROFESSIONAL SOCIETIES

European Society of Therapeutic Radiology and Oncology (EORTC)

American Society of targeted Radiation Oncology (ASTRO)

European Society of Hyperthermic Oncology (ESHO)

American Society of Clinical Oncology (ASCO)

European Society for Radiation Oncology (ESTRO)

Israel Medical Association

Israel Society for Clinical Oncology and Radiation Therapy

10. AWARDS AND HONORS

1992: Robert Reid Newell Memorial Award, Stanford University, California

2010: ISCOR T annual meeting, the best research project.

2014: ISCOR T annual meeting, the best research project.

11. GRADUATE STUDENTS

MD Theses

2012- Noa Shemesh (medical student) The effect of of the sedative pharmacologic combination of Ketamine Morphine and Midazolam on quality of the final days in the terminally ill cancer patients [Rami Ben-Yosef and Noam Asna]

Basic Science

2001- Maya Gibbs, MD (resident in oncology) Liposomal doxorubicin combined with hyperthermia: in vivo results [Alberto Gabison and Rami Ben-Yosef, Co-Supervisor]

2006 Shahar Lev-Ari, PhD, Curcumin and ErbBB's in head and neck, prostate and lung cancer [Dani Aderka, Akiva Vexler and Rami Ben-Yosef, , Co-Supervisor]

2007 Vered Loew, MSc, ErbB4 in prostate cancer [Akiva Vexler and Rami Ben-Yosef, , Co-Supervisor]

2008 Jenny Tenyakov Samra, MSc, ErbB4 in lung cancer. [Akiva Vexler and Rami Ben-Yosef,, Co-Supervisor]

2008 Jamal Lidawi, (resident in Urology) ErbB4 in prostate cancer: in vivo results [Akiva Vexler and Rami Ben-Yosef, , Co-Supervisor]

2009 Sasha Heif, MSc, ErbB4 in head and neck cancer [Akiva Vexler and Rami Ben-Yosef, , Co-Supervisor]

2011 Itai Barnea, PhD, Humanization of ErbB4 antibody [Nadir Arber, Akiva Vexler, Itai Benhar and Rami Ben-Yosef Co-Supervisor]

2012 Mazid Fadi, (resident in oncology) IFP and tumor stem cell cultures (Yuval Shaked, Rami Ben-Yosef Co-Supervisor)

2013 Haitam Nasaralha (resident in oncology), A murine model for radiation induced esphagitis (Yehuda Hovers, Rami Ben-Yosef Co-Supervisor)

2014 Valeria Seministi (resident in oncology), Impact of pelvic radiotherapy on gut microbiota. (Yehuda Hovers, Rami Ben-Yosef Co-Supervisor)

12. RESEARCH GRANTS

1995 British Council, £5000, Radiobiology and ARCON, Rami Ben-Yosef (PI)

- 1996 Israel Cancer Association, 15000₪, ARCON in cancer, Rami Ben-Yosef (PI)
- 1997 Medical Research Foundation of Israel, 45000₪, Hyperthermia and liposomes, Rami Ben-Yosef (PI), Alberto Gabison (Co-I)
- 1998 Israel Cancer Association, 45000₪, Electroporation, hyperthermia and liposomes: *in vitro* and *in vivo* studies, Rami Ben-Yosef (PI), A. Madar (Co-I)
- 1998 Chief Scientist, Ministry of Health, 30000₪, Radiation therapy and invasive fungal infection, Rami Ben-Yosef (PI), A. Polachek (Co-I)
- 2001 Sourasky Medical Center and Weizmann Institute of Science, \$100,000, Repair of oxidative DNA damage as a predictive assay in radiation therapy, Z. Livne (PI) and Rami Ben-Yosef (PI)
- 2001 Tel Aviv University School of Medicine, \$10000, Strontium pharmacokinetics in hormonal resistant prostate cancer patients, Rami Ben-Yosef (PI)
- 2002 Israel Cancer Association, 45000₪, ErbB in H&N cancer, Rami Ben-Yosef (PI)
- 2003 Sourasky Medical Center and Weizmann Institute of Science, \$100,000, Laboratory and clinical aspects of ErbB in cancer, Y. Yarden (PI) and Rami Ben-Yosef (PI)
- 2005 Israel Cancer Association, 45000₪, Curcumin and XRT in H&N cancer, Rami Ben-Yosef (PI) and A. Vexler (Co-I)
- 2006 Tel Aviv University School of Medicine, \$10,000, ErbB4 in prostate cancer, Rami Ben-Yosef (PI) and A. Vexler (Co-I)
- 2006 Tel Aviv University School of Medicine, \$10,000, Curcumin, ErbB4 and XRT in H&N cancer, Rami Ben-Yosef (PI) and A. Vexler (Co-I)
- 2007 Cancer Biology Research Center at Tel-Aviv University, \$10,000, Chimeric anti-ErbB4 Ab's, Rami Ben-Yosef (PI) and A. Vexler (Co-I)
- 2011 Israel Cancer Association, 40000₪, Anti-oxidants in prevention of hearing loss Rami Ben-Yosef (co-I), Arye Gordin (PI)

14. PUBLICATIONS

14.1 Theses

Sleep apnea syndrome in hypertensive patients. Supervisor: Peretz Lavie PhD, The Technion Sleep Laboratories, School of Medicine, Technion, Haifa (1980)

14.2 Refereed papers in professional journals:

Basic Research

1. Surkis R, Rubinrat S, Dagan S, Tzeheval E, Fridkin M, **Ben Yosef R**, Catane R: Polytuftsin: a potential precursor for slow release of the phagocytosis stimulating peptide tuftsin. *Int J Biochem* 22:193-195, 1990.

2. **Ben-Yosef R**, Sullivan D, Kapp DS: Peripheral neuropathy and myonecrosis following hyperthermia and radiation therapy for recurrent prostate cancer: correlation of damage with SAR pattern. *Int J Hyperthermia* 8:173-185, 1992.
3. Prionas SD, Kapp DS, Goffinet DR, Bagshaw MA, **Ben-Yosef R**, Sokol JL, Fessenden P. Interstitial radiofrequency-induced hyperthermia. *Hyperthermic Oncology* 2:249-253, 1992.
4. Sullivan DM, **Ben-Yosef R**, Kapp DS. The Stanford 3D hyperthermia treatment planning - technical review and clinical summary. *Int J Hyperthermia* 9:627-643, 1993.
5. Prionas SD, Kapp DS, Goffinet DR, **Ben-Yosef R**, Fessenden P, Bagshaw MA: Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. *Int J Rad Oncol Biol Phys*, 28:151-162, 1994.
6. **Ben-Yosef R**, Kapp DS. Direct comparison between ultrasound and radiative electro-magnetic hyperthermia devices in malignant tumors. *Int J Hyperthermia* 11:1-10, 1995.
7. **Ben-Yosef R**, Zeira M, Poachek I. The effect of radiation therapy on fungal growth: Results of in vitro and in vivo studies. *J Infect* 50:450-452, 2005.
8. **Ben-Yosef R**, Pelled O, Marko R, Vexler A, Teshuva A, German U, Levita M, Kol R. Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels. *Am J Clin Oncol* 28:138-142, 2005.
9. Starr AN, Vexler A, Konik D, Marmor S, Ashkenasi-Voghera M, Lev-Ari S, Greif Y, **Ben-Yosef R**. Establishment and characterization of a pancreatic carcinoma cell line derived from pleural effusion. *Oncology* 69:239-245, 2005.
10. Lev-Ari S, Zinger H, Kazanov D, Yona D, **Ben-Yosef R**, Starr A, Figer A, Arber N. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. *Biomed Pharmacother* 59:S276-S280, 2005.
11. Starr A, Greif Y, Vexler A, Ashkenazy-Voghera M, Gladesh V, Rubin C, Kerber G, Marmor S, Lev-Ari S, Inbar M, Yarden Y, **Ben-Yosef R**. ErbB4 Increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. *Int J Cancer* 119:269-274, 2006.
12. Lev Ari S, Vexler A, Starr A, **Ben-Yosef R**. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. *Anticancer Res* 26:4423-4430, 2006.
13. Paz-Elizur T, **Ben-Yosef R**, Elinger D, Vexler A, Krupsky M, Berrebi A, Shani A, Schechtman E, Freedman L, Livneh Z. Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head and neck cancer. *Cancer Res* 66:11683-11689, 2006.
14. Lev-Ari S, Kazanov, **Ben-Yosef R**, Arber N. Down regulation of PGE2 by physiological levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell line. *Dig Dis Sci* 52:1128-1133, 2007.

15. Lev-Ari S, Vexler A, Starr A, Lidavi M, Ashkenazy-Voghera M, Loew V, Fenig E, Aderka D, **Ben-Yosef R**. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. *Cancer Investig* 25:411-418, 2007.
16. **Ben-Yosef R**, Lidawi G, Starr A, Karaush V, Loew V, Lev-Ari S, Barnea I, Shtabsky A, Greif Y, Yarden Y, Vexler A. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. *Prostate* 67:871-880, 2007.
17. Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, Benjamin S, Corso S, Gan J, **Ben-Yosef R**, Giordano S, Yarden Y. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. *Oncogene* 26:6968-6978, 2007.
18. Vexler A, Lidawi G, Loew V, Barnea I, Karaush V, Lev-Ari S, Shtabsky A, **Ben-Yosef R**. Anti-ERBB4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies. *Cancer Biol Ther* 7:1090-1094, 2008.
19. **Ben-Yosef R**, Paz A, Levy Y, Alani S, Muncher Y, Shohat S, Domb A, Corn B. A novel device for protecting rectum during prostate cancer irradiation: in vivo data on a large mammal model. *J Urol* 181:1401-1406, 2009.
20. Maimon Y, Karaush V, Yaal-Hahoshen N, **Ben-Yosef R**, Ron I, Vexler A, Lev-Ari S. Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. *J Int Med Res*. 38(6):2033-9, 2010.
21. Barnea I, **Ben-Yosef R**, Karaush V, Benhar I and Vexler A. Targeting EGFR Positive Cancer Cells with Cetuximab-ZZ-PE38: Results of *in vitro* and *in vivo* Studies (Head and Neck. *Head Neck* 35(8): 1171-7, 2012.
22. Barnea I, Haif S, Keshet R, Karaush V, Lev-Ari S, Khafif A, Shtabsky A, Yarden Y, Vexler A and **Ben-Yosef R**. Targeting ErbB-1 and ErbB-4 in Irradiated Head & Neck cancer:Results of in vitro and in vivo studies. *Head Neck* 35:399-407,2013.
23. Levi-Ari S, Starr A, Kazburg S, Berkovich L, Rimmon A, **Ben-Yosef R**, Vexler A Ron I Earon G. Curcumin induces apoptosis and inhibits growth of orthotopic human non small cell lung cancer xenografts. *J Nutr Biochem* 8:843-50, 2014.

Clinical Research

1. Lavie P, **Ben-Yosef R**, Rubin AE. Prevalence of sleep apnea syndrome in essential hypertension. *Am Heart J* 108:372-376, 1984.
2. Gez A, Warner Efrati E, **Ben-Yosef R**, Ben-Baruch N, Yitzhaki N, Uziely B, Brufman G, Biran S. High dose metoclopramide and dexamethasone as an anti-emetic in outpatients receiving chemotherapy for breast cancer. *Oncology* 44:237-239, 1987.

3. Warner E, Sulkes A, Gez E, Uziely B, Ben-Baruch N, **Ben-Yosef R**, Biran S, Catane R. Combined immunotherapy and chemotherapy in the treatment of non small cell carcinoma of the lung. *Chemioterapia* 6 (2 supp) 706-708, 1987.
4. Warner E, Sulkes A, Wheshler Z, Peretz T, **Ben-Yosef R**, Catane R, Biran S. Chemotherapy induction, consolidation chemotherapy and maintenance alternating chemotherapy in small cell carcinoma of the lung. *Isr J Med Sci* 24:593-598, 1988.
5. Wheshler Z, Gez E, Pfeffer MR, **Ben-Yosef R**, Loeventhal E, Fuks Z. Continuous course of megavoltage radiotherapy for carcinoma of the prostate. *Isr J Med Sci* 24:580-583, 1988.
6. Peretz T, Freund HR, Isacson R, **Ben-Yosef R**, Goldien E, Haskel L, Chisin R, Biran S, Durst AL. Treatment of primary and metastatic liver cancer using an Implantable chemoinfusion pump. *Isr J Med Sci* 24:562-567, 1988.
7. Gez E, Brufman G, **Ben-Yosef R**, Catane R, Biran S. A randomized cross-over trial of chlorpromazine and dexamethasone versus high dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy. *Oncology* 46:150-154, 1989.
8. Gabison A, Peretz T, Sulkes A, Amselem S, Druckman S, **Ben-Yosef R**, Catane R, Biran S, Barenholz Y. Systemic administration of doxorubicin containing liposomes in cancer patients. *Eur J Cancer Clin Oncol* 25:1795-1803, 1989.
9. Peretz TY, **Ben-Yosef R**, Lebensart P, Finkstein R, Biran S, Durst AL, Krausz MM. Hepatic intradermal antibiotic therapy for resistant hepatic abscess. *Int Surg* 744:171-174, 1989.
10. Catane R, **Ben-Yosef R**, Livni N, Rosenmman E, Eshar Z. Monoclonal antibodies against carcinoembryonic antigen (CEA) may discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors. *Nat Imm Cell Growth Regul* 9:203-208, 1990.
11. **Ben-Yosef R**, Glaser B, Catane R. Somatostatine analogue (SMS 201-995) in the treatment of gut neuroendocrine tumors. *Harefuah* 119:15-17, 1990.
12. **Ben-Yosef R**, Kapp DS. Hyperthermia and radiation therapy in the treatment of cancer metastatic to the penis. *J Urol* 148:67-71, 1992.
13. Kapp DS, Cox RS, Barnett TA, **Ben-Yosef R**. Thermoradiotherapy for residual microscopic cancer: Elective or post-excisional hyperthermia therapy in the management of local-regional treatment breast cancer. *Int J Rad Oncol Biol Phys* 24:261-277, 1992.
14. **Ben-Yosef R**, Kapp DS. Persistent and/or late complications of combined radiation therapy and hyperthermia. *Int J Hyperthermia* 8:733-745, 1992.
15. Bagshaw MA, **Ben-Yosef R**, Fessenden P, Goffinet DR, Kaplan ID, Kapp DS, Lohrbach AW, Mariscal JM, Peters-Brown AN, Prionas SD, Smitt MC, Sokol JL. Combined interstitial irradiation and hyperthermia in the treatment of prostatic cancer. *Hyperthermic Oncology* 2:363-368, 1992.
16. **Ben-Yosef R**, Kapp DS. Long term survival in metastatic malignant melanoma treated with combined radiation therapy and hyperthermia. *Int J Hyperthermia* 9:767-781, 1993.

17. Stein M, Spencer D, Kantor A, Lakier R, Lachter J, **Ben-Yosef R**, Bezwoda WR. Radiation therapy in epidemic, AIDS-related Kaposi's sarcoma in Southern Africa. *Tumori* 80:216-219, 1994.
18. Stein ME, **Ben-Yosef R**, Drumea K, Spencer D. Lymphomas associated with the endemic (African) variant of Kaposi's sarcoma: A chemosensitive but fatal entity. *Eur J Cancer* 30A:2183, 1994.
19. Prionas SD, Kapp DS, Goffinet DR, **Ben-Yosef R**, Fessenden F, Bagshaw MA: Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. *Int J Rad Oncol Biol Phys* 28:151-162, 1994.
20. **Ben-Yosef R**, Kapp DS. Direct clinical comparison of ultrasound and radiative electromagnetic hyperthermia applicators in the same tumours. *Int J Hyperthermia* 11:1-10, 1995.
21. **Ben-Yosef R**, Hoppe RH: The treatment of early stage gastric lymphoma. *J Surg Oncol* 57:78-86, 1994.
22. **Ben-Yosef R**, Braverman I, Saah D, Nagler R, Shohat S, Nagler A. Mucosal melanoma following autologous stem cell transplantation for non-Hodgkin's lymphoma (NHL). *Bone Marrow Transplant* 18:1017-1019, 1996.
23. **Ben-Yosef R**, Or R, Nagler A, Slavin S. Graft vs. tumor and graft versus leukaemia effect in patient with concurrent breast cancer and acute myeloid leukaemia. *Lancet* 348:1242-1243, 1996.
24. Lashevsky I, **Ben-Yosef R**, Rinkevich D, Reisner S, Markiewicz W. Intrapericardial minocycline sclerosis for malignant pericardial effusion. *Chest* 109:452-454, 1996.
25. **Ben-Yosef R**. Radiation recall dermatitis. *Lancet* 348:1321, 1996.
26. **Ben-Yosef R**, Or R, Naparstek E, Kapelushnik J, Varadi G, Slavin S, Nagler A. Should soybean agglutinin (SBA) purging be performed in breast cancer patients undergoing autologous stem cell transplantation (ASCT)? A retrospective analysis of 48 patients. *Am J Clin Oncol* 20:419-423, 1997.
27. Nagler A, Ackerstein A, Ben-Shahar M, Or R, Naparstek E, **Ben-Yosef R**, Slavin S. Continuous interleukin-2 infusion combined with cyclophosphamide based combination chemotherapy in the treatment of hemato-oncological malignancies. Results of a phase I-II study. *Acta Hematol* 100:63-68, 1998.
28. Lyass O, Uziely B, **Ben-Yosef R**, Heshing NI, Lotem M, Libson E, Brufman G, Gabison A. Dose scheduling study of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer after prior chemotherapy cancer. *Cancer* 89:1037-1047, 2000.
29. **Ben-Yosef R**, Hyperthermia and radiation therapy in cancer patients. *Harefuah* 2002;141:418-420
30. **Ben-Yosef R**, Zeira M, Gabison A. Hyperthermia and liposomal encapsulated doxorubicin. *Isr Med Assoc J* 5:407-409, 2003.
31. **Ben-Yosef R**, Vigler N, Inbar M, Vexler A. Hyperthermia combined with radiation therapy in the treatment of local recurrent breast cancer. *Isr Med Assoc J* 6:392-395, 2004.

32. **Ben-Yosef R**, Soifer R, Vexler A. Radiation therapy in cancer patients with psoriasis. The fractionated daily dose and the Koebner phenomenon. *Radiother Oncol* 74:21-23, 2005.
33. **Ben-Yosef R**, Pelled O, Marko R, Vexler A, Teshuva A, German U, Levita M, Kol R. Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels. *Am J Clin Oncol* 28:138-142, 2005.
34. Sperber F, Weinstein Y, Sarid D, **Ben-Yosef R**, Shalmon A, Yaal-Hahoshen N. Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer. *Isr Med Assoc J* 8:342-346, 2006.
35. Khafif A, Schneebaum S, Fliss DM, Lerman H, Metser U, **Ben-Yosef R**, Gil Z, Reider L, Trejo E, Livshitz E, Even-Sapir E. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system in oral cavity squamous cell carcinoma. *Head Neck* 28:874-879, 2006.
36. **Ben-Yosef R**, Marmor S, Starr A, Matceyevsky D, Khafif A, Vexler A. ErbB4 expression in squamous cell carcinoma of head and neck. *Target Oncol* 1:181-185, 2006.
37. Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, **Ben-Yosef R**, Marmor S, Grinberg Y, Maimon N, weinstein Y, Yaal-Hahoshen N. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: A Phase II study. *Clin Dug Investig* 26: 691-701, 2006.
38. Matceyevsky D, Vexler A, Asna N, Khafif A, Inbar M, **Ben-Yosef R**. Dead sea products for radiochemotherapy-induced acute skin and mucosal toxicity in patients with head and neck cancer. *Isr Med Assoc J* 9:439-442, 2007.
39. **Ben-Yosef R**, Sarid D, Vexler A, Lidawi G, Inbar M, Marmor S, Starr A, Yaal Hahoshen N. Nuclear and cytoplasmic expression of ErbB4 in prostate cancer. *Int J Biol Markers* 22:181-185, 2007.
40. Khafif A, **Ben-Yosef R**, Kesler A, Asna N, Landsberg R, Patchornik H, Even-Sapir E, Fliss DM. The sensitivity of preoperative scanning in regional recurrence of papillary thyroid cancer. *Otolaryngol Head Neck Surg* 2007;137:412-415
41. Khafif A, Posen J, Yagil Y, Beiser M, Gil Z, **Ben-Yosef R**, Landsberg R, Fliss DM. Quality of life in patients older than 75 following major head and neck surgery. *Head Neck* 2007;29:932-939
42. Khafif A, **Ben-Yosef R**, Abergel A, Kesler A, Landsberg R, Fliss DM. Elective paratracheal neck dissection for lateral metastases from papillary carcinoma of the thyroid: Is it indicated? *Head Neck* 2008;30:306-310
43. **Ben-Yosef R**, Yaal-Hahoshen N. Dead Sea products. *Isr Med Assoc J* 10:765, 2007.
44. **Ben-Yosef R**, Sarid D, Barnea I, Marmor S, Stavesky S, Vexler A, Starr A, Yaal Hachoshen N. ErbB1-ErbB4 over-expression ethnicity and predicted outcome in prostate cancer. *Target Oncol* 3:13-17, 2008.
45. Sarid D, Ron IG, Shoshan L, Barnea I, Shina S, Baratz M, Greenberg J, Merimsky O, **Ben-Yosef R**, Lev-Ari S, Keidar Y, Yaal-Hahoshen N. Invasive breast cancer treated with taxol and

- epirubicin neo-adjuvant chemotherapy: the role in the outcome of the "crosstalk" between Erb receptors and p53. *Anticancer Res* 28:3147-3152, 2008.
46. Safra T, Greenberg J, Ron IG, **Ben-Yosef R**, Inbar M, Sarid D, Yaal-Hahoshen N. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment? *Isr Med Assoc J* 10:339-343, 2008.
 47. Eisen T, Oudard S, Szczylik C, TARGET Study Group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. *J Natl Cancer Inst* 100(20), 2008.
 48. Khafif A, Lev-Ari S, Vexler A, Barnea I, Staar A, Karaush V, Heif S, **Ben-Yosef R**. Curcumin - a potential radiosensitizer in head and neck cancer. *Laryngoscope* 119:2019-2026, 2009.
 49. Stahl S, Barney Y, Weiss J, Amir A, Zaretski A, Leshem D, Miller E, Shafrir R, **Ben-Yosef R**, Gur E. Treatment of earlobe keloids by extralesional excision combined with preoperative and postoperative "sandwich" radiotherapy. *Plast Reconstr Surg* 125:135-141, 2010.
 50. Kaidar-Person O, Bortnyak-Abdah R, Amit A, Berniger A, **Ben-Yosef R**, Kuten A. Current principles for radiotherapy in cervical cancer. *Med Oncol.* 29:2919-22, 2012.
 51. Kaidar-Person O, Bortnyak-Abdah R, Amit A, Berniger A, **Ben-Yosef R**, Kuten A The role of imaging in the management of non-metastatic cervical cancer. *Med Oncol* 29:3389-93, 2012.
 52. Grünwald V, Karakiewicz PI, Bavbek SE, REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. *Eur J Cancer* 48:324-32, 2012.
 53. Gez E, Cytron S, **Ben-Yosef R**, London L, Corn B, Alani S, Scarzello G, DalMoro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Muncher Y, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovács D, Garg M. Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. *Radiation Oncology* 8:96, 2013.
 54. Melchert C, Gez E, Garg M, Bohlen G, Kalnicki S, Scarzello G, Koziol I, Anscher M, Cytron S, Paz A, Torre T, Bassignani M, Dal Moro F, Jocham D, **Ben Yosef R**, Kovács G. Interstitial Biodegradable Balloon for Rectal Dose Reduction: Results of comparison pre- and postimplant virtual treatment plans of patients participating in a Prospective Multi-Center Study. *Radioth Oncol* 106:210-4, 2013.
 55. Kaidar Person O, Abdah-Bortnyak R, Amit A, Nevelsky A, Berniger A, Bar-Daroma R, **Ben-Yosef R** and Kuten A. Tolerance of the vaginal vault to high dose rate brachytherapy and concomitant chemo-pelvic irradiation: long term perspective. *Rep Pract Oncol Radiother* 19:56-61, 2013.

56. Nevelsky A, Leumwananonthachai N, Kaidar-Person O, Bar-Daroma R, Nasrallah H, **Ben-Yosef R** and Kuten A. Hipocampal sparing whole brain radiotherapy using Elekta equipment. *J Appl Clin Med Pys* 14:4205, 2013
57. Parker C, Nilsson S, Heinrich D,; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 369:213-23, 2013.
58. Stein ME, Zidan J, Charas T, Drumea K, **Ben-Yosef R**. Anaplastic variant of classical seminoma of the testis: northern Israel oncology center experience and brief review of literature. *Rambam Maimonides Med J* 5:1, 2014
59. Stein ME, Drumea K, Charas T, Gershuny A, **Ben-Yosef R**. Platinum-based Chemotherapy in Primary Advanced Seminoma-a Retrospective Analysis: Treatment Results at the Northern Israel Oncology Center (1989-2010). *Rambam Maimonides Med J* 5:1, 2014
60. Stein ME, Zidan J, Charas T Gershuny A, **Ben-Yosef R**. Bleomycin induced pneumonitis in three patients treated with chemotherapy for primary advanced seminoma. *J BUEON* 20:928-32, 2015
61. Stein ME, Zidan J, Charas T and **Ben-Yosef R**. Radiotherap for stage IIA seminoma. The northern Israel oncology center experience 1971-2010. *Rep Pract Oncol Radiother* 19:281-6, 2014.
62. Stein ME, Charas, T Drumea K Sabo E and **Ben-Yosef R**. Spermatocytic variant of classic seminoma: a report of five cases and a brief review of the literature. *Rambam Maimonides Med J*, 5:3, 2014.
63. Bolla M; Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, van der Steen Banasik EM, Armstrong J, **Ben-Yosef R**, Coens C, van den Bergh AC and Collette L. Short androgen suppression and radiation dose escalation for intermediate and high risk localized prostate cancer: Results of EORTC Trial 22991. *J clin Oncol* 34:1748-56, 2016
64. Zur M, Shai A, Levirov M, Bitterman A, Shilone E, **Ben-Yosef R** and Steiner M. Short term complications of intra-operative radiotherapy for early breast cancer. *J Surg Oncolo* 113: 370-3, 2016

Case reports

1. **Ben-Yosef R**, Catane R, Libson A, Chisin R, Kaplan N, Atlan H. Nuclear magnetic resonance in the diagnosis of cord compression. *Harefuah* 111:39-41, 1986.
2. Gez A, **Ben-Yosef R**, Libson E, Biran S. The use of utilizing hormone-releasing hormone analogues in the treatment of prostatic carcinoma. *Harefuah* 112:239-240, 1987.
3. **Ben-Yosef R**, Pfeffer R, Gez E, Catane R. The management of malignant pericardial effusion. *Harefuah* 115:138-141, 1988.
4. **Ben-Yosef R**, Warner E, Gez E, Catane R. Malignant pericardial effusion as a sign of metastatic rectal cancer: a case report and survey of the literature. *J Chemotherapy* 1:342-345, 1989.

5. **Ben-Yosef R**, Gez E, Catane R. Acute pericarditis following bleomycin: A case report and literature analysis. *J Chemotherapy* 2:70-71, 1990.
6. Asna N, Cohen Y, **Ben-Yosef R**. Primary radiation therapy for solitary chloroma of oral tongue. *Isr Med Assoc J* 5:452, 2003.
7. Kaidar-Person O, Amit A, Berniger A, **Ben-Yosef R**, Kuten A, Bortnyak-Abdah R. Primary signet-ring cell adenocarcinoma of the uterine cervix: case report and review of the literature. *Eur J Gynaecol Oncol.* 34(4):353-4, 2013.
8. Rozin AP, Nierenberg G, Vlodaysky E Tledano K, Meushar N, Yassin K and Ben-Yosef R. Pigmented vilonodular synovitis for combined therapy *J Med Cases* 5:147-151, 2014.

Review papers

1. Fessenden P, Lee ER, Kapp DS, Zhou LJ, Wilsey T, Tarczy-Hornoch P, McEuen AH, Samulski TV, Tanabe E, Lohrbach AW, Peters Brown AN, Prionas SD, **Ben-Yosef R**. Review of the Stanford experience developing non-focusing scanning and array surface microwave (MW) applicators. *Hyperthermic Oncology* 2:183-186, 1992.
2. Slavin S, Or R, Nagler A, Kapleushnik Y, Varadi G, **Ben-Yosef R**, Ackerstein A, Naparstek E. Bone marrow transplantation. *Harefuah* 129:31-38, 1995.
3. **Ben-Yosef R**. Radiation therapy in benign diseases. *Harefuah* 133:606-610, 1997.
4. **Ben-Yosef R**. Autologous stem cell transplantation in metastatic breast cancer patients. *Harefuah* 134:780-785, 1998.
5. **Ben Yosef R**, Ron I. Radiation therapy for pain relief in patients with bony metastases secondary to bone metastases. *Eur Pharmacother* 32-36, 2005.
6. Kaidar-Person O, Bortnyak-Abdah R, Amit A, Berniger A, **Ben-Yosef R**, Kuten A. The role of imaging in the management of non-metastatic cervical cancer. *Med Oncol* 5:3389-93, 2012.
7. Kaidar-Person O, Bortnyak-Abdah R, Amit A, Berniger A, **Ben-Yosef R**, Kuten A. Current principles for radiotherapy in cervical cancer. *Med Oncol* 4:2919-22, 2012.

14.3 Books

None

14.4 Book chapters

1. Slavin S, Morecki S, Naparstek E, Nagler A, Varadi G, **Ben-Yosef R**, Or R. Adoptive allogeneic cell-mediated immunotherapy and the use of non-myeloablative stem cell transplantation for hematologic malignancies, genetic diseases and metastatic solid tumors. In: Bariett et al, eds. 1999.

14.5 Letters to the Editor

1. Stein ME, Kantor A, Lakier R, **Ben-Yosef R**, Bezwoda WR. Endemic African Kaposi's sarcoma in an elderly population - a very radiosensitive disease. *Radiother Oncol* 30:182-183, 1994.

2. **Ben-Yosef R**, Catane R. The management of patients with metastatic cancer of unknown origin. Harefuah 111:54-55, 1986.
3. **Ben-Yosef R**, Partial breast irradiation- Is it the time for prime-time? Isr Med Ass. J; 14:254-5, 2012.
- 4.

14.6 Refereed papers in conference proceedings

1. **Ben-Yosef R**, Heres T, Berniger A, Carmi R, Ivovich I and Genesin Y. Perineal Biodegradable Balloon Is Effective for Both Sparing the Rectum and as a Fiducial Marker in Prostate Cancer Patients Treated With Mild Hypofractionation Intern J Rad Oncol Biol Phy 87: S360–S36, 2013.
2. Lutsyk, M, Mezied, F, Epelbaum, R, **Ben-Yosef R**, Is the Outcome Following Chemo-Radiation Equivalent to R1/R2 Resection Adjuvant Chemotherapy in Stage I-III Pancreatic Cancer?. Radiological Society of North America 2014
3. Charas T, Bar-Deroma R, **Ben-Yosef R**, Berniger A, Epelbaum R. Update of the Israeli Experience With Iodine-131 Metaiodobenzylguanidine Therapy for Patients With Malignant Pheochromocytoma, Paraganglioma, and Other NETs. Intern J Rad Oncol Biol Phy 93: E198, 2015.
4. Kaidar-Person O, Musalem S, Epelbaum R, Haim N, Ben-Yosef R, Shullman K. Does old age matter in the treatment of locally advanced rectal cancer? A single center experience. ESTRO forum EP 1276, 2015.

14.7 Patents

Itai Benhar, Akiva Vexler, Itai Barnea and Rami Ben-Yosef. Cetuxumab with ZZ-PE38 in cancer treatment, 2010.

Gary Marks, Akiva Vexler and Rami Ben-Yosef. IFP in cancer cell cultures, 2012.

14.8 Other publications

None

15. CONFERENCES

15.1 Plenary, keynote or invited talks

Ben-Yosef R. Timing of Hyperthermia in trimodality approach in local recurrent breast cancer, Prague 2016. (invited talk).

15.2 Contributed Talks and Posters

1. Steiner M, Leviov M, Hadari N and **Ben-Yosef R**. Intra-operative radiotherapy by whole breast irradiation in early breast cancer. 2nd world congress on controversies in breast cancer 2016.

15.3 Participation in organizing conference

16. SIGNIFICANT PROFESSIONAL PROJECTS/ACTIVITIES

2010-present: EORTC- member in radiotherapy group. Our radiotherapy unit (technicians physicists and MD's) take an active role in this group.and participate in phase II-III clinical studies.

2016- A cooperation with Insightec (HIFU guided MRI in the treatment of cancer patients) is merging

- A. Conception and participation in design
- B. Collection of data and conduct of substantial part of the experimental work
- C. Analysis and interpretation of results
- D. Drafting and/or substantial editing the manuscript

Basic Research (2013-present)

- 22. Barnea I, Haif S, Keshet R, Karaush V, Lev-Ari S, Khafif A, Shtabsky A, Yarden Y, Vexler A and **Ben-Yosef R**. Targeting ErbB-1 and ErbB-4 in Irradiated Head & Neck cancer: Results of in vitro and in vivo studies. *Head Neck* 35:399-407, 2013. (A, C, D)
- 23. Levi-Ari S, Starr A, Kazburg S, Berkovich L, Rimmon A, **Ben-Yosef R**, Vexler A Ron I Earon G. Curcumin induces apoptosis and inhibits growth of orthotopic human non small cell lung cancer xenografts. *J Nutr Biochem* 8:843-50, 2014. (A)

Clinical Research (2013-present)

- 53. Gez E, Cytron S, **Ben-Yosef R**, London L, Corn B, Alani S, Scarzello G, DalMoro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Muncher Y, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovács D, Garg M. Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. *Radiation Oncology* 8:96, 2013. (A,B,C,D)
- 54. Melchert C, Gez E, Garg M, Bohlen G, Kalnicki S, Scarzello G, Koziol I, Anscher M, Cytron S, Paz A, Torre T, Bassignani M, Dal Moro F, Jocham D, **Ben Yosef R**, Kovács G. Interstitial Biodegradable Balloon for Rectal Dose Reduction: Results of comparison pre- and postimplant virtual treatment plans of patients participating in a Prospective Multi-Center Study. *Radioth Oncol* 106:210-4, 2013. (A,B,C,D)
- 55. Kaidar Person O, Abdah-Bortnyak R, Amit A, Nevelsky A, Berniger A, Bar-Daroma R, **Ben-Yosef R** and Kuten A. Tolerance of the vaginal vault to high dose rate brachytherapy and concomitant chemo-pelvic irradiation: long term perspective. *Rep Pract Oncol Radiother* 19:56-61, 2013. (A,C,D)
- 56. Nevelsky A, Leumwananonthachai N, Kaidar-Person O, Bar-Daroma R, Nasrallah H, **Ben-Yosef R** and Kuten A. Hippocampal sparing whole brain radiotherapy using Elekta equipment. *J Appl Clin Med Pys* 14:4205, 2013 (A,B,C)
- 57. Parker C, Nilsson S, Heinrich D,; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 369:213-23, 2013. (B)

58. Stein ME, Zidan J, Charas T, Drumea K, **Ben-Yosef R**. Anaplastic variant of classical seminoma of the testis: northern Israel oncology center experience and brief review of literature. *Rambam Maimonides Med J* 5:1, 2014 (**A,C,D**)
59. Stein ME, Drumea K, Charas T, Gershuny A, **Ben-Yosef R**. Platinum-based Chemotherapy in Primary Advanced Seminoma-a Retrospective Analysis: Treatment Results at the Northern Israel Oncology Center (1989-2010). *Rambam Maimonides Med J* 5:1, 2014 (**A,C,D**)
60. Stein ME, Zidan J, Charas T Gershuny A, **Ben-Yosef R**. Bleomycin induced pneumonitis in three patients treated with chemotherapy for primary advanced seminoma. *J BUEON* 20:928-32, 2015 (**A,C,D**)
61. Stein ME, Zidan J, Charas T and **Ben-Yosef R**. Radiotherap for stage IIA seminoma. The northern Israel oncology center experience 1971-2010. *Rep Pract Oncol Radiother* 19:281-6, 2014. (**A,C,D**)
62. Stein ME, Charas, T Drumea K Sabo E and **Ben-Yosef R**. Spermatocytic variant of classic seminoma: a report of five cases and a brief review of the literature. *Rambam Maimonides Med J*, 5:3, 2014. (**A,C,D**)
63. Bolla M; Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, van der Steen Banasik EM, Armstrong J, **Ben-Yosef R**, Coens C, van den Bergh AC and Collette L. Short androgen suppression and radiation dose escalation for intermediate and high risk localized prostate cancer: Results of EORTC Trial 22991. *J clin Oncol* 34:1748-56, 2016 (**B,D**)
64. Zur M, Shai A, Levirov M, Bitterman A, Shilone E, **Ben-Yosef R** and Steiner M. Short term complications of intra-operative radiotherapy for early breast cancer. *J Surg Oncolo* 113: 370-3, 2016 (**C,D**)

הפקולטה לרפואה ע"ש רפפורט

הטכניון - מכון טכנולוגי לישראל

תאריך: 12.7.2016

ריכוז פעילות הוראה לשנת הלימודים 2016

שם המרצה: פרופ' רחמים בן- יוסף

תאריך	מקום/מחלקה	קבוצה/שנה	נושא	שיטה	משך
2016	מכון הקרינה	רביעית-שישית	מבוא לרדיותרפיה	ראה פירוט מטה	יום מרוכז (7 שעות)

הוראה לקבוצות הסטודנטים בשנים הקליניות מתקיימת מזה שנים במכון הקרינה ברמב"ם. מספר הקבוצות בשנה 8-12. בשנה האחרונה גם הקבוצות המסונפות לביה"ח הכרמל/מרכז רפואי לין מגיעות אלינו ליום מרוכז. עד לפני שנה- גם הקבוצות מביה"ס לרפואה בבר אילן (צפת) הגיעו אלינו להדרכה זו. ההוראה ביום המרוכז כוללת:

שיחת פתיחה והרצאת מבוא (עקרונות בפיזיקה רפואית/רדיוביולוגיה) (שעה אחת)

קבלת חולים חדשים במרפאת הרדיותרפיה (3 שעות)

סיור במכון קרינה (שעה אחת)

הרצאת סיכום (רדיותרפיה קלינית) (שעה אחת)

שיחת סיכום/משוב (חצי שעה).

עד שנת 2014 העברתי אנוכי את ההרצאות/שיחת סיכום ומשוב. החל משנת 2015 ואילך הרופאים המומחים, בתורם, מעבירים את הרצאת המבוא והרצאת הסיכום. כל רופאי המכון, כולל אנוכי, משתתפים בהדרכה במרפאת הרדיותרפיה. את שיחת הפתיחה ושיחת סיכום/משוב-אנוכי עושה.